AUGX vs. NOTE, ZFOX, AMWL, DHX, RSSS, HGBL, MNY, SWVL, STCN, and SCOR
Should you be buying Augmedix stock or one of its competitors? The main competitors of Augmedix include FiscalNote (NOTE), ZeroFox (ZFOX), American Well (AMWL), DHI Group (DHX), Research Solutions (RSSS), Heritage Global (HGBL), MoneyHero (MNY), Swvl (SWVL), Steel Connect (STCN), and comScore (SCOR). These companies are all part of the "business services, not elsewhere classified" industry.
FiscalNote (NYSE:NOTE) and Augmedix (NASDAQ:AUGX) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
54.3% of FiscalNote shares are held by institutional investors. Comparatively, 87.1% of Augmedix shares are held by institutional investors. 47.6% of FiscalNote shares are held by company insiders. Comparatively, 11.0% of Augmedix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, FiscalNote had 1 more articles in the media than Augmedix. MarketBeat recorded 3 mentions for FiscalNote and 2 mentions for Augmedix. FiscalNote's average media sentiment score of 0.62 beat Augmedix's score of 0.23 indicating that Augmedix is being referred to more favorably in the news media.
FiscalNote received 67 more outperform votes than Augmedix when rated by MarketBeat users. Likewise, 69.61% of users gave FiscalNote an outperform vote while only 50.00% of users gave Augmedix an outperform vote.
FiscalNote presently has a consensus price target of $4.44, indicating a potential upside of 246.68%. Augmedix has a consensus price target of $3.88, indicating a potential upside of 322.07%. Given FiscalNote's higher possible upside, analysts plainly believe Augmedix is more favorable than FiscalNote.
FiscalNote has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Augmedix has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500.
Augmedix has lower revenue, but higher earnings than FiscalNote. FiscalNote is trading at a lower price-to-earnings ratio than Augmedix, indicating that it is currently the more affordable of the two stocks.
Augmedix has a net margin of -41.95% compared to Augmedix's net margin of -48.89%. Augmedix's return on equity of -141.98% beat FiscalNote's return on equity.
Summary
FiscalNote beats Augmedix on 11 of the 17 factors compared between the two stocks.
Get Augmedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AUGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Augmedix Competitors List
Related Companies and Tools
